Related Experiment Video
Updated: Apr 28, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
10.7K
Acute liver failure in Turkey: a systematic review
Cüneyt Kayaalp1, Veysel Ersan, Sezai Yılmaz
1Department of Gastrointestinal Surgery, Liver Transplantation Institute, İnönü University, Malatya, Turkey.
Summary
Hepatitis A and B are leading causes of acute liver failure in Turkey, alongside cryptogenic and metabolic factors. Preventable causes like viral hepatitis and intoxication highlight the need for vaccination and public awareness.
Area of Science:
- Hepatology
- Public Health
- Toxicology
Background:
- Acute liver failure (ALF) presents a significant global health challenge.
- Understanding regional etiologies is crucial for targeted prevention and treatment strategies.
Purpose of the Study:
- To delineate the primary causes and contributing factors of acute liver failure (ALF) specifically within the Turkish population.
- To analyze patient demographics, etiological agents, treatment modalities, and outcomes.
Main Methods:
- A comprehensive literature search of international and national medical databases was conducted.
- Data from a dedicated acute liver failure center in Turkey were integrated.
- Patient data were retrospectively analyzed for age, gender, etiology, treatment, and outcomes.
Main Results:
- Hepatitis A and B were the most prevalent causes of ALF in children and adults, respectively.
- Cryptogenic, metabolic (e.g., Wilson's disease), and toxic factors (mushroom, firework intoxication) were significant contributors.
- Drug-induced ALF was primarily linked to anti-tuberculosis agents; paracetamol was a rare cause. Transplanted patients showed significantly better survival rates.
Conclusions:
- Preventable etiologies, including viral hepatitis and specific intoxications, underscore the importance of vaccination and public health campaigns in Turkey.
- While paracetamol is not currently a major cause of ALF, its over-the-counter availability warrants continued monitoring.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:26Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
357
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
357
01:23Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
01:29Hepatic Encephalopathy
46
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
46